Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Acrivon Therapeutics, Inc. (ACRV : NSDQ)

• Company Description    Acrivon Therapeutics Inc. is a clinical stage biopharmaceutical company developing precision oncology medicines which matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon's proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics. The company's lead candidate includes ACR-368. Acrivon Therapeutics Inc. is based in WATERTOWN, Mass. Number of Employees: 78

• Price / Volume Information    Yesterday's Closing Price: $1.88 Daily Weekly Monthly 20 Day Moving Average: 1,105,795 shares Shares Outstanding: 31.46 (millions) Market Capitalization: $59.14 (millions) Beta: 1.82 52 Week High: $8.66 52 Week Low: $1.05 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.73% 0.04% 12 Week 39.26% 33.49% Year To Date -68.77% -72.70%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 480 ARSENAL WAY SUITE 100 - WATERTOWN,MA 02472 USA ph: 617-207-8979 fax: - alevy@acrivon.com http://www.acrivon.com

• General Corporate Information    Officers Peter Blume-Jensen - Chief Executive Officer; President and Chairman of Kristina Masson - Executive Vice President Rasmus Holm-Jorgensen - Chief Financial Officer Katharine Peterson - Chief Accounting Officer Sharon Shacham - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 004890109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 31.46 Most Recent Split Date: (:1) Beta: 1.82 Market Capitalization: $59.14 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.59 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.20 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.41 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -5.77% vs. Previous Quarter: -7.84% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -50.78 03/31/25 - -44.66 ROA 09/30/25 - - 06/30/25 - -46.08 03/31/25 - -40.94 Current Ratio 09/30/25 - - 06/30/25 - 10.31 03/31/25 - 11.17 Quick Ratio 09/30/25 - - 06/30/25 - 10.31 03/31/25 - 11.17 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 4.56 03/31/25 - 5.12 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©